Downstream targets of the BCR such as SYK, Bruton’s tyrosine kinase (BTK), or PI3K isoform p110 delta have a promising anti-neoplastic activity in patients with CLL. Here, BTK is linked to B-cell chronic lymphocytic leukemia.